Alkermes

Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alkermes reports robust Q4 earnings, eyes growth through innovative products

Alkermes demonstrated strong financial performance in Q4 2022, driven by the successful launch of LYBALVI and continued growth in key products.
The company's focus on expanding market access, enhancing product awareness, and strategic investments position it for future success and revenue growth.
Challenges in meeting revenue targets, managing profitability, and refining market strategies require careful navigation and proactive decision-making.
Opportunities in advancing product launches, expanding the pipeline, and leveraging scientific advancements offer avenues for sustained growth and market leadership.

Alkermes reports robust Q1 earnings, eyes global expansion and innovation

Alkermes delivered strong financial results in Q1 2023, driven by key proprietary products and strategic initiatives like the LYBALVI direct-to-consumer campaign.
While facing challenges such as commercial pressures and financial optimization queries, the company remains focused on growth and profitability.
Opportunities for international expansion, strategic investments, and innovative drug development position Alkermes for future success and value creation for shareholders.

Alkermes reports strong Q2 earnings, eyes growth through strategic initiatives

Alkermes' Q2 2023 Earnings Call reflects robust financial performance, strategic focus on key products, and ongoing investment in growth opportunities. Resolving arbitration, strong net income, and cash position underscore financial strength amidst operational challenges.

Alkermes posts solid Q3 results, plans neuroscience focus post-separation

Alkermes delivered strong Q3 results with revenue growth across key products and a focus on disciplined cost management post-separation.
The company showcased promising data for ALKS 2680 and outlined strategic priorities to drive future growth in the neuroscience sector.
While challenges like managing expenses and addressing safety concerns exist, opportunities in expanding product offerings and market access strategies are key for future success.
Investors should monitor Alkermes' progress in optimizing dosing profiles, mitigating adverse events, and achieving profitability targets amidst competitive pressures.

Alkermes reports stellar 2023 results, eyes transformative neuroscience advancements

Alkermes' strong financial performance in 2023 sets the stage for continued growth and innovation in 2024.
Key products like LYBALVI, ARISTADA, and VIVITROL demonstrated robust sales growth, underpinning the company's success.
Addressing challenges such as liver toxicity and visual disturbances will be crucial for sustaining growth and product development.
Opportunities in advancing neuroscience studies and capital allocation strategies position Alkermes for future success and value creation.

Alkermes reports strong Q1 earnings, eyes growth through product differentiation

Alkermes' Q1 performance reflects solid revenue growth and profitability, driven by key product successes.
While facing challenges such as expense management and market access, the company remains well-positioned.
Opportunities for growth lie in expanding prescriber base, accelerating revenue, and leveraging product strengths.
Overall, Alkermes demonstrates financial resilience and strategic focus on sustainable growth.

Alkermes (ALKS) reports robust Q2 earnings, focuses on growth strategies

Alkermes (ALKS) delivered strong revenue performance in Q2 2024, driven by proprietary product growth and effective expense management.
The company showcased resilience amidst revenue challenges and emphasized strategic initiatives for profitability and pipeline advancement.
While facing industry challenges, Alkermes remains poised for growth through innovation, market expansion, and operational efficiency.
Strategic focus on advancing key products, exploring growth opportunities, and prudent financial management underpin Alkermes' growth trajectory.

Alkermes excels in Q3 earnings, targets $200M EBITDA in 2025

Alkermes demonstrated strong sales performance in Q3 2024, with a strategic focus on profitability and cash flow for the future. While facing challenges in certain revenue streams, the company is poised to capitalize on growth opportunities and drive financial success in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Allakos Inc

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Alkermes, Allakos See Activist Action

-- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project -- -- Application Period Open Until Nov. 30, 2022 -- DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it is now accepting applications for its annual Alkermes Pathways Research Awards® program.

Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program

Alkermes plc has a slew of revenue earning products in CNS. It is refocusing itself on oncology assets.

Alkermes: Nothing Stands Out As Interesting

̶  Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference  ̶ DUBLIN , Sept. 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio at Psych Congress, which began on Sept.

Alkermes Showcases Research from Psychiatry Portfolio at Psych Congress

Editas Medicine

GlaxoSmithKline

Immunovant Inc

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance

Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Alkermes (ALKS) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Denali Therapeutics

Novavax

S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past five years through Aug. 9.

3 Companies Growing Revenue Fast

Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Alkermes (ALKS) Loses 16.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada.

Alkermes' (ALKS) Earnings & Revenues Surpass Estimates in Q2

Alkermes plc. (NASDAQ:ALKS ) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Iain Brown - CFO Todd Nichols - CCO Richard Pops - CEO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Chris Shibutani - Goldman Sachs Umer Raffat - Evercore ISI Amy Li - Jefferies Paul Matteis - Stifel Marc Goodman - SVB Leerink Douglas Tsao - H.C.

Alkermes plc (ALKS) CEO Richard Pops on Q2 2022 Results - Earnings Call Transcript

Alkermes (ALKS) delivered earnings and revenue surprises of 50% and 1.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Q2 Earnings and Revenues Top Estimates

—    Second Quarter Revenues of $276.2 Million Reflect Strong Growth in Proprietary Net Sales — —    GAAP Loss per Share of $0.18 and Non-GAAP Earnings per Share of $0. 06 — —    Raises Financial Expectations for Full-Year 2022— DUBLIN , July 27, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2022 and provided updated financial expectations for full-year 2022.

Alkermes plc Reports Second Quarter 2022 Financial Results

Biogen

Bristol-Myers

Teva Pharmaceutical

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

Alkermes' (ALKS) second-quarter 2022 results set to report earnings and revenues figures and provide updates on its portfolio of marketed drugs.

Is a Beat in Store for Alkermes (ALKS) This Earnings Season?

BancFirst

ExlService Holdings

Alkermes plc (ALKS), BancFirst (BANF) and ExlService (EXLS) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

3 Stocks With Momentum Anomaly to Buy on Solid Earnings Rally

DUBLIN , July 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

Alkermes to Report Second Quarter Financial Results on July 27, 2022

Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Alkermes (ALKS) Keep the Earnings Surprise Streak Alive?

Does Alkermes (ALKS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Alkermes (ALKS) is a Great Momentum Stock to Buy

All Board Nominees Overwhelmingly Elected by Shareholders DUBLIN , July 7, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the results of its 2022 Annual General Meeting of Shareholders (the "Annual Meeting") held July 7, 2022. All four of the Board's nominees — Emily Peterson Alva, Cato T.

Alkermes Announces Results of Annual General Meeting of Shareholders

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement on Alkermes PLC (NASDAQ: ALKS) regarding how it intends to vote at the upcoming Alkermes annual meeting and the reasons therefor: Richard Pops, the CEO and Chairman of Alkermes, has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago. Despite Alkermes growing revenues in the last five years and having annual revenues exceeding $1

Sarissa Capital Comments on Alkermes Annual Meeting

Bellus Health Inc

Geron

Immunocore Holdings

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

DUBLIN , June 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 2:40 p.m. PT (5:40 p.m.

Alkermes to Participate in the Goldman Sachs Healthcare Conference

– Competitive Grants Program Application Period to Begin on June 15, 2022 – DUBLIN , June 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on June 15, 2022. Now in its sixth year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.

Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

DUBLIN , June 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:30 p.m. ET (7:30 p.m.

Alkermes to Participate in the Jefferies Healthcare Conference

– ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types – – Company to Host Investor Webcast on June 6 at 8:00 a.m. ET –  DUBLIN , June 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy.

News for Alkermes Stock (ALKS)